Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05627323 · ClinicalTrials.gov registry record · Phase 1
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
A Phase 1 study of Glioblastoma Multiforme of Brain, sponsored by Chimeric Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT05627323 is a Phase 1 study of Glioblastoma Multiforme of Brain that is active but no longer recruiting, run by Chimeric Therapeutics. The registered enrollment target is 42 participants, below the 155-participant average among 11 other Glioblastoma Multiforme of Brain trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05627323, a Phase 1 study of Glioblastoma Multiforme of Brain, is active but no longer recruiting, sponsored by Chimeric Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).
Conditions Studied
Interventions
- BIOLOGICAL CHM-1101 CAR-T cells
Study Locations (2)
California
- City of Hope Medical Center - Duarte
Texas
- St. David's South Austin Medical Center - Sarah Cannon - Austin - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2041-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05627323
The ClinicalTrials.gov registry entry for NCT05627323 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 155-participant average among 11 other Glioblastoma Multiforme of Brain trials with a reported enrollment target (73% lower). The listed sponsor is Chimeric Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme of Brain appearing as the primary indexed condition, and to 1 intervention - of which CHM-1101 CAR-T cells is the first listed.
NCT05627323 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT05627323 about?
NCT05627323 is a clinical study titled "CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma". This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come ba...
What is the current status of trial NCT05627323?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-06-06. Estimated completion is 2041-01.
What conditions does trial NCT05627323 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme of Brain.
What interventions are being tested in trial NCT05627323?
The interventions under investigation include: CHM-1101 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05627323?
This trial is sponsored by Chimeric Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05627323 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme of Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
RECRUITING · Phase 1
-
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
RECRUITING · Phase 1
-
Trial of C134 in Patients With Recurrent GBM
ACTIVE NOT RECRUITING · Phase 1
-
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
RECRUITING
-
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
RECRUITING
-
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.